Jamison, T., Jabbour, E., Jain, N., Karrar, O., Haddad, F., Kebriaei, P., Khouri, I., Popat, U., Yang, H., Senapati, J., Kugler, E., Garris, R., Garcia-Manero, G., Kantarjian, H., Short, N. (2025). Latency between detectable low-level measurable residual disease (MRD) by next-generation sequencing and overt relapse following flow cytometry MRD-negative remission in patients with acute lymphoblastic leukemia: Implications for the optimal frequency of MRD monitoring. Blood. https://doi.org/10.1182/blood-2025-1558